Xin Lang Cai Jing·2026-03-27 06:53Core Viewpoint - Tiger Med has seen a significant stock price increase, with a 5% rise on March 27, bringing the share price to 53.32 yuan, and a total market capitalization of 459.10 billion yuan. The stock has risen for three consecutive days, accumulating a total increase of 6.82% during this period [1][4]. Company Overview - Hangzhou Tiger Medical Technology Co., Ltd. was established on December 15, 2004, and went public on August 17, 2012. The company specializes in providing professional clinical research services for domestic and international pharmaceutical and health-related products. Its business scope includes I to IV phase clinical trial technical services, data management and statistical analysis, registration application, on-site clinical trial services, SMO services, medical testing services, medical document translation, medical imaging diagnosis services, and training services [1][4]. - The revenue composition of the company's main business includes: clinical trial-related services and laboratory services (52.60%), clinical trial technical services (45.21%), and other supplementary services (2.19%) [1][4]. Fund Holdings - According to data, one fund under Rongtong Fund holds a significant position in Tiger Med. The Rongtong Healthcare Industry Mixed A/B Fund (161616) held 604,700 shares in the fourth quarter, accounting for 5.07% of the fund's net value, making it the second-largest holding. The estimated floating profit for today is approximately 1.54 million yuan, with a total floating profit of 1.96 million yuan during the three-day increase [2][5]. - The Rongtong Healthcare Industry Mixed A/B Fund was established on July 26, 2012, with a current scale of 599 million yuan. Year-to-date, the fund has experienced a loss of 2.95%, ranking 6478 out of 8898 in its category. Over the past year, it has gained 5.27%, ranking 6075 out of 8181, and since inception, it has achieved a return of 117.98% [2][5].